Compare VET & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VET | GENB |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2004 | N/A |
| Metric | VET | GENB |
|---|---|---|
| Price | $12.44 | $11.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $15.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 3.1M | 364.6K |
| Earning Date | 05-06-2026 | 05-03-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.01 | N/A |
| Revenue Next Year | $3.02 | $45.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.90 | $11.00 |
| 52 Week High | $14.82 | $14.21 |
| Indicator | VET | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 44.08 |
| Support Level | $7.42 | $11.21 |
| Resistance Level | $14.55 | $13.69 |
| Average True Range (ATR) | 0.61 | 1.12 |
| MACD | -0.21 | -0.10 |
| Stochastic Oscillator | 7.11 | 9.65 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.